CEO van de Winkel wants long tenure at Genmab

Jan van de Winkel, CEO of Genmab, sees himself staying at Genmab for a long time, which the company’s chair, Deirdre P. Connelly welcomes.

Jan van de Winkel, CEO of Genmab | Photo: Mik Eskestad/ERH

The CEO of Genmab, Jan van de Winkel, hopes to continue leading the Danish biotech giant for several years, he replied when asked about his future plans on Monday at a press event in connection with the firm’s AGM.

This is evidently supported by Genmab’s chair of the board of directors, Deirdre P. Connelly:

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs